Oncotelic Therapeutics, Inc. financial data

Symbol
OTLC on OTC
Location
29397 Agoura Rd., #107, Aguora Hills, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.86 % -46.3%
Debt-to-equity 229 %
Return On Equity -52 % -388%
Return On Assets -14.7 % -256%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 435M shares +7.05%
Common Stock, Shares, Outstanding 408M shares +0.25%
Common Stock, Value, Issued 4.08M USD +0.25%
Weighted Average Number of Shares Outstanding, Basic 408M shares +1.67%
Weighted Average Number of Shares Outstanding, Diluted 453M shares +12.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 70K USD
Research and Development Expense 21.2K USD
General and Administrative Expense 279K USD -30.1%
Operating Income (Loss) -3.48M USD -968%
Nonoperating Income (Expense) -701K USD +40.5%
Net Income (Loss) Attributable to Parent -3.93M USD -217%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 88K USD +21.9%
Accounts Receivable, after Allowance for Credit Loss, Current 19K USD 0%
Assets, Current 138K USD -28.3%
Goodwill 2.79M USD -53.4%
Assets 26.7M USD -10.9%
Accounts Payable, Current 343K USD -82.4%
Liabilities, Current 19.3M USD +19%
Liabilities 19.3M USD +4.64%
Retained Earnings (Accumulated Deficit) -38.1M USD -11.5%
Stockholders' Equity Attributable to Parent 8.3M USD -31.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 7.39M USD -35.7%
Liabilities and Equity 26.7M USD -10.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -167K USD +27.9%
Net Cash Provided by (Used in) Financing Activities 160K USD -36%
Common Stock, Shares Authorized 750M shares 0%
Common Stock, Shares, Issued 408M shares +0.25%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.96K USD -137%
Interest Paid, Excluding Capitalized Interest, Operating Activities 94.8K USD 0%
Deferred Tax Assets, Valuation Allowance 12.8M USD -4.71%
Deferred Tax Assets, Gross 12.8M USD -4.71%
Deferred Tax Assets, Operating Loss Carryforwards 10M USD -4.43%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15M shares 0%
Additional Paid in Capital 42.3M USD +0.14%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 0 USD
Interest Expense 885K USD -71.1%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%